CombiMatrix Corporation (NASDAQ:CBMX), through its wholly owned subsidiary, CombiMatrix Diagnostics (“CMDX”), is a CAP/CLIA certified molecular diagnostics laboratory offering comprehensive profiling of chromosomes and genes for both oncology and pre- and postnatal developmental disorders. CombiMatrix Diagnostics offers a comprehensive and proprietary analysis of cancer tumors at the DNA, or molecular level. The Company has quickly earned reputation as a molecular diagnostics company that performs DNA-based testing services for cancer and developmental disorders. The Company took a major step towards prominence when it announced that diagnostics industry veteran Jeff Hayes has been named Director of Sales for the Oncology market. Hayes is a renowned name in the biopharmaceutical and cancer diagnostics industries and has over two decades of experience in the sector. Jeff Hayes has held an array of positions which stem from marketing management positions with Schering-Plough and Eli Lilly to sales management roles with US LABS and PLUS Diagnostics.
Judd Jessup, President and CEO of CombiMatrix credits the strategies of the Company as a key attribute in generating sales and adding names to the clientele. Jeff puts up, “Having worked with Jeff in the past, I have first-hand knowledge of his skill and professional sales aptitude, especially when it comes to introducing new cancer testing services. I am certain that he is the right choice for this important role”
CombiMatrix has developed a unique approach to analyzing a patient’s cancer which provides both prognostic and therapeutic information by analyzing hundreds of key OncoGenes at once with personalized state-of-the-art results. To enhance the value of the company, Hayes will be heading the sales efforts of CombiMatrix’s DNAarray test portfolio which include DNAarray Heme Profile, the DNAarray Tumor Profile and the DNAarray Breast Profile.
Shares of CBMX are up 1.59% to $2.56.
The assembled information distributed by headlineotc.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Headlineotc.com does expect that investors will buy and sell securities based on information assembled and presented herein. Headlineotc.com will not be responsible in any way for or accept any liability for any losses arising from an investor’s reliance on or use of information obtained from our website or emails. PLEASE always do your own due diligence, and consult your financial advisor.